This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context | MicrobiomeTrials
← Back to trials NCT03577041
Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context Recruiting OBSERVATIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2020-01-29Est. Completion: 2026-06
Enrollment target: 600 participantsLocations CHU Amiens, Amiens, France Other microbiome trials you might be interested in Retinal Disease AMD Retinal Degeneration Retinitis Pigmentosa
Background:
\- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macu…
Bethesda, United States
Geographic Atrophy Secondary to Age-related Macular Degeneration
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacopl…
Phoenix, United States Completed Sep 5, 2025
Age-Related Macular Degeneration
Background:
* Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 55 years of …